Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. However, a challenging macroeconomic scenario continues to plague Globus Medical. The stock ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target of $100.00. The company’s shares closed last ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick ...

Globus Medical, Inc.’s GMED growth in the third quarter can be attributed to the robust prospect in the musculoskeletal space. The company’s merger with NuVasive is expected to generate ...

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares opened today at $92.41. Leverage the power of ...

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

The most recent guidance for Globus Medical (GMED) was reported on January 8, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $3.40 to $3.50 ...

Short interest in Globus Medical Inc (NYSE:GMED) decreased during the last reporting period, falling from 2.79M to 2.44M. This put 2.4% of the company's publicly available shares short.

The company currently has its sales operations distributed across 51 counties worldwide. GMED boasts a Growth Style Score of A and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating.